#8707 on the rich list of 14,644 insiders
Marshall Urist
EVP, Research & Investments at Royalty Pharma. Based in New York, New York.
$10.1M
in disclosed stock, −$142K (−1.38%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
- Rank
- 8707th of 14,644
- Companies held
- 1
- Largest holding
- RPRX, 100.0% of total
- Latest SEC filing
- Nov 16, 2026
What the $10.1M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Royalty Pharma RPRX Class A Ordinary Shares | Through Sandy Lamm LLC | 125,000 | $67.72 | $8.5M | 83.7% | Form 4, Nov 16, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Through IRA | 19,020 | $67.72 | $1.3M | 12.7% | Form 4, Nov 16, 2026 |
| Royalty Pharma RPRX Class A Ordinary Shares | Directly | 5,341 | $67.72 | $362K | 3.6% | Form 4, Nov 16, 2026 |
Share counts are the amounts Marshall Urist reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Sold | RPRX | 23,592 | $69.47 | $1.6M | View |
| Nov 16, 2026 | Sold | RPRX | 1,408 | $69.99 | $99K | View |
| Oct 5, 2026 | Sold | RPRX | 4,126 | $57.10 | $236K | View |
| Sep 28, 2026 | Sold | RPRX | 4,126 | $57.88 | $239K | View |
| Jul 1, 2026 | Sold | RPRX | 9,099 | $55.88 | $508K | View |
| Jun 24, 2026 | Sold | RPRX | 9,098 | $55.18 | $502K | View |
| May 20, 2026 | Sold | RPRX | 13,684 | $52.75 | $722K | View |
| May 14, 2026 | Sold | RPRX | 13,684 | $53.06 | $726K | View |
| Jan 30, 2026 | Sold | RPRX | 20,000 | $41.09 | $822K | View |
| Jan 23, 2026 | Sold | RPRX | 20,000 | $40.26 | $805K | View |
| Jan 16, 2026 | Sold | RPRX | 20,000 | $39.52 | $790K | View |
| Jan 9, 2026 | Sold | RPRX | 20,000 | $40.78 | $816K | View |
| Jan 2, 2026 | Sold | RPRX | 20,000 | $38.48 | $770K | View |
| Dec 26, 2025 | Sold | RPRX | 20,000 | $39.32 | $786K | View |
| Dec 19, 2025 | Sold | RPRX | 20,000 | $38.38 | $768K | View |
| Dec 16, 2025 | Sold | RPRX | 20,000 | $38.32 | $766K | View |
| Dec 5, 2025 | Sold | RPRX | 23,334 | $39.15 | $914K | View |
| Dec 5, 2025 | Sold | RPRX | 18,242 | $39.15 | $714K | View |
| Dec 1, 2025 | Sold | RPRX | 18,242 | $39.90 | $728K | View |
| Dec 1, 2025 | Sold | RPRX | 23,333 | $39.93 | $932K | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 8704 | Shawn Vadala Chief Financial Officer, Mettler-Toledo International. Columbus, OH | $10.1M |
| 8705 | Scipio Maximus Carnecchia Chief Executive Officer, Mitek Systems. Centennial, CO | $10.1M |
| 8706 | Abhey Lamba Chief Financial Officer, RingCentral. Belmont, CA | $10.1M |
| 8707 | Marshall Urist EVP, Research & Investments, Royalty Pharma. New York, NY | $10.1M |
| 8708 | Julio M. Quintana Director, Newmont. Indianapolis, IN | $10.1M |
| 8709 | Stanley M. Kuriyama Director, Matson. Honolulu, HI | $10.1M |
| 8710 | David John Newman Chief Underwriting Officer, Bowhead Specialty Holdings. New York, NY | $10.1M |
Other Royalty Pharma insiders
All RPRX insiders- Pablo G. Legorreta$335MCEO, Chairman of the Board. #516 overall
- George W. Lloyd$184MEVP, Investments & CLO. #939 overall
- Terrance P. Coyne$132MEVP & CFO. #1225 overall
- James F. Reddoch$57.3MEVP & Chief Scientific Officer. #2308 overall
- Rory B. Riggs$28.5MDirector. #2663 overall
- Christopher Hite$13.6MEVP & Chairman, Partnering. #6964 overall
Questions
How much stock does Marshall Urist own?
Marshall Urist holds $10,114,727 in listed stock based on SEC filings and current prices, mostly Royalty Pharma (RPRX). That ranks 8707th on the Stock Rich List.
Is this Marshall Urist's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Marshall Urist last buy or sell stock?
The most recent open-market trade on file is a sale of 23,592 RPRX shares on Nov 16, 2026 at $69.47.